Harald Wajant

ResearcherID Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 28

Top Topics

Rheumatoid Arthritis

Multiple Myeloma

Lipopolysaccharide Induced

Top Venues

Cell death & disease

Proceedings of the National Academy of Sciences of the United States of America

This page only lists publications with an associated author ORCID identifier.

Publications

Nienke Hesen, Mohamed Anany, Andre Freidel, Mediya Baker, Daniela Siegmund, Olena Zaitseva, Harald Wajant, Isabell Lang
Genetically engineered IgG1 and nanobody oligomers acquire strong intrinsic CD40 agonism. Bioengineered 15 (1) (2024)
Nienke Hesen, Mohamed Anany, Andre Freidel, Mediya Baker, Daniela Siegmund, Olena Zaitseva, Harald Wajant, Isabell Lang
Genetically engineered IgG1 and nanobody oligomers acquire strong intrinsic CD40 agonism. Bioengineered 15 (1) (2024)
Nienke Hesen, Mohamed Anany, Andre Freidel, Mediya Baker, Daniela Siegmund, Olena Zaitseva, Harald Wajant, Isabell Lang
Genetically engineered IgG1 and nanobody oligomers acquire strong intrinsic CD40 agonism. Bioengineered 15 (1) (2024)
Nienke Hesen, Mohamed Anany, Andre Freidel, Mediya Baker, Daniela Siegmund, Olena Zaitseva, Harald Wajant, Isabell Lang
Genetically engineered IgG1 and nanobody oligomers acquire strong intrinsic CD40 agonism. Bioengineered 15 (1) (2024)
Nienke Hesen, Mohamed Anany, Andre Freidel, Mediya Baker, Daniela Siegmund, Olena Zaitseva, Harald Wajant, Isabell Lang
Genetically engineered IgG1 and nanobody oligomers acquire strong intrinsic CD40 agonism. Bioengineered 15 (1) (2024)
Daniela Siegmund, Harald Wajant
TNF and TNF receptors as therapeutic targets for rheumatic diseases and beyond. Nature reviews. Rheumatology (2023)
Constanze Schanbacher, Heike M Hermanns, Kristina Lorenz, Harald Wajant, Isabell Lang
Complement 1q/Tumor Necrosis Factor-Related Proteins (CTRPs): Structure, Receptors and Signaling. Biomedicines 11 (2) (2023)
Constanze Schanbacher, Heike M Hermanns, Kristina Lorenz, Harald Wajant, Isabell Lang
Complement 1q/Tumor Necrosis Factor-Related Proteins (CTRPs): Structure, Receptors and Signaling. Biomedicines 11 (2) (2023)
Constanze Schanbacher, Heike M Hermanns, Kristina Lorenz, Harald Wajant, Isabell Lang
Complement 1q/Tumor Necrosis Factor-Related Proteins (CTRPs): Structure, Receptors and Signaling. Biomedicines 11 (2) (2023)
Juliane Medler, Kirstin Kucka, Harald Wajant
Tumor Necrosis Factor Receptor 2 (TNFR2): An Emerging Target in Cancer Therapy. Cancers 14 (11) (2022)
Daniela Siegmund, Jennifer Wagner, Harald Wajant
TNF Receptor Associated Factor 2 (TRAF2) Signaling in Cancer. Cancers 14 (16) (2022)
Isabell Lang, Olena Zaitseva, Harald Wajant
FcγRs and Their Relevance for the Activity of Anti-CD40 Antibodies. International journal of molecular sciences 23 (21) (2022)
Natalia Ortí-Casañ, Inge S Zuhorn, Petrus J W Naudé, Peter Paul de Deyn, Pauline E M van Schaik, Harald Wajant, Ulrich L M Eisel
A TNF receptor 2 agonist ameliorates neuropathology and improves cognition in an Alzheimer's disease mouse model. Proceedings of the National Academy of Sciences of the United States of America 119 (37) (2022)
Johannes Nelke, Juliane Medler, Daniela Weisenberger, Andreas Beilhack, Harald Wajant
CD40- and CD95-specific antibody single chain-Baff fusion proteins display BaffR-, TACI- and BCMA-restricted agonism. mAbs 12 (1) (2021)
Emilie Ronin, Charlotte Pouchy, Maryam Khosravi, Morgane Hilaire, Sylvie Grégoire, Armanda Casrouge, Sahar Kassem, David Sleurs, Gaëlle H Martin, Noémie Chanson, Yannis Lombardi, Guilhem Lalle, Harald Wajant, Cédric Auffray, Bruno Lucas, Gilles Marodon, Yenkel Grinberg-Bleyer, Benoit L Salomon
Tissue-restricted control of established central nervous system autoimmunity by TNF receptor 2-expressing Treg cells. Proceedings of the National Academy of Sciences of the United States of America 118 (13) (2021)
Ahmed Aido, Olena Zaitseva, Harald Wajant, Matej Buzgo, Aiva Simaite
Anti-Fn14 Antibody-Conjugated Nanoparticles Display Membrane TWEAK-Like Agonism. Pharmaceutics 13 (7) (2021)
Kirstin Kucka, Isabell Lang, Tengyu Zhang, Daniela Siegmund, Juliane Medler, Harald Wajant
Membrane lymphotoxin-α2β is a novel tumor necrosis factor (TNF) receptor 2 (TNFR2) agonist. Cell death & disease 12 (4) (2021)
Nadine Weinelt, Christos Karathanasis, Sonja Smith, Juliane Medler, Sebastian Malkusch, Simone Fulda, Harald Wajant, Mike Heilemann, Sjoerd J L van Wijk
Quantitative single-molecule imaging of TNFR1 reveals zafirlukast as antagonist of TNFR1 clustering and TNFα-induced NF-ĸB signaling. Journal of leukocyte biology 109 (2) (2020)
Umair Munawar, Markus Roth, Santiago Barrio, Harald Wajant, Daniela Siegmund, Ralf C Bargou, Klaus Martin Kortüm, Thorsten Stühmer
Assessment of TP53 lesions for p53 system functionality and drug resistance in multiple myeloma using an isogenic cell line model. Scientific reports 9 (1) (2019)
Juliane Medler, Johannes Nelke, Daniela Weisenberger, Tim Steinfatt, Moritz Rothaug, Susanne Berr, Thomas Hünig, Andreas Beilhack, Harald Wajant
TNFRSF receptor-specific antibody fusion proteins with targeting controlled FcγR-independent agonistic activity. Cell death & disease 10 (3) (2019)
Mohamed El-Mesery, Tina Rosenthal, Hilka Rauert-Wunderlich, Martin Schreder, Thorsten Stühmer, Ellen Leich, Andreas Schlosser, Martin Ehrenschwender, Harald Wajant, Daniela Siegmund
The NEDD8-activating enzyme inhibitor MLN4924 sensitizes a TNFR1+ subgroup of multiple myeloma cells for TNF-induced cell death. Cell death & disease 10 (8) (2019)
Simone Füllsack, Alevtina Rosenthal, Harald Wajant, Daniela Siegmund
Redundant and receptor-specific activities of TRADD, RIPK1 and FADD in death receptor signaling. Cell death & disease 10 (2) (2019)
Mohamed A Anany, Jennifer Kreckel, Simone Füllsack, Alevtina Rosenthal, Christoph Otto, Daniela Siegmund, Harald Wajant
Soluble TNF-like weak inducer of apoptosis (TWEAK) enhances poly(I:C)-induced RIPK1-mediated necroptosis. Cell death & disease 9 (11) (2018)
Alyaa Hatem Ibrahim, Eman Zekry Attia, Dina Hajjar, Mohamed A Anany, Samar Yehia Desoukey, Mostafa Ahmed Fouad, Mohamed Salah Kamel, Harald Wajant, Tobias A M Gulder, Usama Ramadan Abdelmohsen
New Cytotoxic Cyclic Peptide from the Marine Sponge-Associated Nocardiopsis sp. UR67. Marine drugs 16 (9) (2018)
Delphine Cuchet-Lourenço, Davide Eletto, Changxin Wu, Vincent Plagnol, Olivier Papapietro, James Curtis, Lourdes Ceron-Gutierrez, Chris M Bacon, Scott Hackett, Badr M Rasheed Alsaleem, Mailis Maes, Miguel Gaspar, Ali Alisaac, Emma Goss, Eman AlIdrissi, Daniela Siegmund, Harald Wajant, Dinakantha Kumararatne, Mofareh S AlZahrani, Peter D Arkwright, Mario Abinun, Rainer Doffinger, Sergey Nejentsev
Biallelic RIPK1 mutations in humans cause severe immunodeficiency, arthritis, and intestinal inflammation. Science (New York, N.Y.) 361 (6404) (2018)
Daniela Siegmund, Martin Ehrenschwender, Harald Wajant
TNFR2 unlocks a RIPK1 kinase activity-dependent mode of proinflammatory TNFR1 signaling. Cell death & disease 9 (9) (2018)
Harald Wajant
TRAIL- and TNF-induced signaling complexes-so similar yet so different. The EMBO journal 36 (9) (2017)
Martin Chopra, Marlene Biehl, Tim Steinfatt, Andreas Brandl, Juliane Kums, Jorge Amich, Martin Vaeth, Janina Kuen, Rafaela Holtappels, Jürgen Podlech, Anja Mottok, Sabrina Kraus, Ana-Laura Jordán-Garrote, Carina A Bäuerlein, Christian Brede, Eliana Ribechini, Andrea Fick, Axel Seher, Johannes Polz, Katja J Ottmüller, Jeanette Baker, Hidekazu Nishikii, Miriam Ritz, Katharina Mattenheimer, Stefanie Schwinn, Thorsten Winter, Viktoria Schäfer, Sven Krappmann, Hermann Einsele, Thomas D Müller, Matthias J Reddehase, Manfred B Lutz, Daniela N Männel, Friederike Berberich-Siebelt, Harald Wajant, Andreas Beilhack
Exogenous TNFR2 activation protects from acute GvHD via host T reg cell expansion. The Journal of experimental medicine 213 (9) (2016)